P/E at 37.55 vs Industry's 36.24: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Parity

The current P/E of 37.55 for Sun Pharmaceutical Industries Ltd is marginally higher than the industry average of 36.24, signalling a valuation premium of approximately 3.7%. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, potentially reflecting confidence in its earnings stability or growth prospects. However, the difference is not stark enough to indicate an extreme overvaluation. The sector itself is characterised by a broad range of valuations, with some companies trading at significant discounts or premiums, making this positioning relatively balanced.

Given the pharmaceutical sector’s sensitivity to regulatory changes, patent cliffs, and R&D outcomes, this valuation premium may also incorporate expectations of resilience or innovation from Sun Pharmaceutical Industries Ltd. Sun Pharma’s market capitalisation of ₹4,65,267.04 crores places it firmly in the large-cap category, which often commands a valuation premium due to perceived stability and liquidity.

Performance Across Timeframes: Strong Medium-Term Gains

Examining the stock’s returns reveals a compelling divergence between short and medium-term performance. Over the past three months, Sun Pharmaceutical Industries Ltd has surged 15.76%, significantly outperforming the Sensex, which declined by 1.11% during the same period. This strong quarterly performance contrasts with the one-day return of -0.56%, which was slightly below the Sensex’s 0.57% gain, indicating some short-term profit-taking or consolidation.

Year-to-date, the stock has appreciated 12.76%, again outperforming the Sensex’s negative 8.91%. Over the one-year horizon, the stock’s 13.80% gain is notable against the Sensex’s 5.64% loss, underscoring sustained outperformance. Longer-term returns are even more impressive, with three-year gains of 79.95% versus the Sensex’s 16.57%, and five-year returns of 181.59% compared to the Sensex’s 46.07%. However, the ten-year return of 151.71% trails the Sensex’s 178.86%, reflecting a period of relative underperformance in the more distant past.

This pattern of strong medium-term gains coupled with some short-term volatility raises the question should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The data suggests a stock that has regained momentum but remains subject to near-term fluctuations.

Moving Average Configuration: Bullish Across All Key Levels

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a broad-based uptrend across short, medium, and long-term horizons. This configuration is often interpreted as a strong bullish signal, indicating that recent price momentum is supported by sustained buying interest.

Trading just 0.58% below its 52-week high of ₹1962.5, the stock is close to its peak levels for the year, reinforcing the strength of the current trend. This technical strength complements the fundamental outperformance seen in the medium term. However, the one-day decline of 0.56% suggests some short-term profit-taking or market hesitation, which is typical in stocks approaching all-time highs.

Given this setup, is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently, with a blend of positive, flat, and negative performances across constituent stocks. Sun Pharmaceutical Industries Ltd stands out as a relative outperformer within this environment, particularly over the medium term. Its 3-month return of 15.76% contrasts with the sector’s more muted or negative returns, highlighting its leadership position.

This outperformance may be attributed to the company’s diversified product portfolio, global footprint, and ongoing investments in research and development. The sector’s inherent volatility, driven by regulatory scrutiny and patent expiries, means that such relative strength is noteworthy. What factors are driving this divergence within the sector? The answer lies in the company’s operational execution and market positioning.

Rating Reassessment: Previously Hold, Now Updated

On 8 June 2026, Sun Pharmaceutical Industries Ltd had its rating updated from a previous Hold status, as per MarketsMOJO records. While the current rating is not disclosed, the reassessment reflects a significant shift in the company’s evaluation based on recent data. The Mojo Score of 72.0 indicates a solid overall assessment, factoring in valuation, performance, technicals, and sector context.

This rating update coincides with the stock’s strong medium-term performance and positive technical indicators, suggesting that the reassessment was driven by improved fundamentals and market positioning. Previously rated Hold, what is Sun Pharmaceutical Industries Ltd's current rating? The four-parameter analysis factors in the valuation premium and momentum signals.

Conclusion: Data Reflects a Balanced Yet Bullish Outlook

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a modest premium to its sector, supported by strong medium-term performance and a bullish technical setup. The stock’s outperformance relative to the Sensex and its sector over one, three, and five-year periods underscores its resilience and growth trajectory.

While short-term volatility is evident in the recent one-day decline, the overall moving average configuration and proximity to 52-week highs suggest sustained investor confidence. The rating reassessment from Hold to a new status reflects this evolving outlook, though the precise direction remains undisclosed. Should investors consider this data as a signal to adjust their holdings in Sun Pharmaceutical Industries Ltd?

Ultimately, the interplay of valuation, performance, technicals, and sector dynamics offers a comprehensive view of the stock’s current standing in the market.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today